Skip to main content Accessibility help

Effects of Antiparkinson Medication on Cognition in Parkinson’s Disease: A Systematic Review

  • Marc-André Roy (a1), Maxime Doiron (a1) (a2), Jessica Talon-Croteau (a1), Nicolas Dupré (a2) (a3) and Martine Simard (a1)...


Objective: This study aimed to systematically review the effects of currently prescribed antiparkinson medication on cognition in patients with mild-to-moderate Parkinson’s disease (PD) who were either cognitively intact or mildly impaired. Methods: English- and French-language studies published between 1969 and 2017 were accessed via MedLine, PsychNET, EMBASE and EBSCO databases. Methodological quality (MQ) was evaluated with the quality assessment instrument of the Cochrane Collaboration Depression, Anxiety and Neurosis Review (scores from 0% to 44% indicate very low quality; scores from 45% to 64% indicate low quality; scores from 65% to 84% indicate medium quality; and scores from 85% to 100% indicate high quality). Hedges’ g and Student’s t-test were performed on all cognitive outcome measures reported. Results: In total, 14 studies assessed the cognitive effects of levodopa (L-D), pramipexole (PRX), selegiline (SEL) and rasagiline (RAS) in mild-to-moderate non-demented PD patients. The MQ was overall low, with an average score of 49.1%. Results for L-D showed deleterious effects on a test of cognitive inhibition, as well as benefits on tests of attention/processing speed/working memory, executive functions and episodic memory. Pramipexole was associated with a worsening of episodic memory and impulse control. Results on SEL indicated a deterioration of global cognition over time and of concept formation. Rasagiline had some benefits on working memory and verbal fluency. Conclusion: Antiparkinson medications can have deleterious (L-D; PRX; SEL) and beneficial (L-D; RAS) effects on cognition. However, randomized double-blind placebo-controlled trials with larger sample sizes are required to better elucidate this issue.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effects of Antiparkinson Medication on Cognition in Parkinson’s Disease: A Systematic Review
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effects of Antiparkinson Medication on Cognition in Parkinson’s Disease: A Systematic Review
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effects of Antiparkinson Medication on Cognition in Parkinson’s Disease: A Systematic Review
      Available formats


Corresponding author

Correspondence to: Marc-André Roy, School of Psychology, Laval University, Pav. F.-A. Savard, 2325 rue des Bibliothèques, Quebec City, QC, Canada, G1V 0A6. Email:


Hide All
1. Litvan, I, Goldman, JG, Tröster, AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27:349-356.
2. Lawrence, BJ, Gasson, N, Loftus, AM. Prevalence and subtypes of mild cognitive impairment in Parkinson’s disease. Sci Rep, 2016; 6.
3. Weintraub, D, Simuni, T, Caspell‐Garcia, C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mo Disord. 2015;30(7):919-927.
4. Santangelo, G, Vitale, C, Picillo, M, et al. Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219-1226.
5. Wang, YQ, Tang, BS, Yan, XX, et al. A neurophysiological profile in Parkinson’s disease with mild cognitive impairment and dementia in China. J Clin Neurosci. 2015;22(6):981-985.
6. Hobson, P, Meara, J. Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16‐year outcome evaluation of the Denbighshire cohort. Int J Geriatr Psychiatry. 2015;30:1048-1055.
7. Kalbe, E, Rehberg, SP, Heber, I, et al. Subtypes of mild cognitive impairment in patients with Parkinson’s disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry. 2016;87(10):1099-1105.
8. Pfeiffer, HCV, Løkkegaard, A, Zoetmulder, M, Friberg, L, Werdelin, L. Cognitive impairment in early‐stage non‐demented Parkinson’s disease patients. Acta Neurol Scand. 2014;129:307-318.
9. Yarnall, AJ, Breen, DP, Duncan, GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD Study. Neurology. 2014;82:308-316.
10. Pigott, K, Rick, J, Xie, SX, et al. Longitudinal study of normal cognition in Parkinson disease. Neurology. 2015;85(15):1276-1282.
11. Bohnen, NI, Kaufer, DI, Hendrickson, R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and Parkinsonian dementia. J Neurol. 2006;253:242-247.
12. Calabresi, P, Picconi, B, Parnetti, L, Di Filippo, M. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine–acetylcholine synaptic balance. Lancet Neurol. 2006;5:974-983.
13. Kish, SJ, Tong, J, Hornykiewicz, O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain. 2008;131:120-131.
14. Vazey, E, Aston-Jones, G. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson’s disease. Front Behav Neurosci. 2012;6:48.
15. Ye, Z, Altena, E, Nombela, C, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain. 2014;137(4):1145-1155.
16. Cools, R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev. 2006;30:1-23.
17. Poletti, M, Bonuccelli, U. Orbital and ventromedial prefrontal cortex functioning in Parkinson’s disease: neuropsychological evidence. Brain Cogn. 2012;79:23-33.
18. Agid, Y, Javoy-Agid, F, Ruberg, M. Biochemistry of neurotransmitters in Parkinson’s disease. Mov Disord. 1987;2:166-230.
19. Gotham, AM, Brown, RG, Marsden, CD. ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain. 1988;111:299-321.
20. Jellinger, KA. Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J Neural Transm. 2013;120:157-167.
21. Matsumoto, M. Dopamine signals and physiological origin of cognitive dysfunction in Parkinson’s disease. Mov Disord. 2015;30:472-483.
22. Poletti, M, Bonuccelli, U. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review. Ther Adv Psychopharmacol. 2013;3:101-113.
23. Grimes, D, Gordon, J, Snelgrove, B, et al. [Canadian guidelines on Parkinson’s Disease]. Can J Neurol Sci. 2012;39:S1-S30; French.
24. Gibb, WR, Lees, AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
25. Gelb, DJ, Oliver, E, Gilman, S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33-39.
26. Hoehn, MM, Yahr, MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
27. Goetz, CG, Poewe, W, Rascol, O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord. 2004;19:1020-1028.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Revised. Washington, DC: American Psychiatric Association; 1987, 608pp.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. text revision. Washington, DC: American Psychiatric Association; 2000, 943pp.
30. Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
31. Dubois, B, Burn, D, Goetz, C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22:2314-2324.
32. Moncrieff, J, Churchill, R, Drummond, DC, McGuire, H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. Int J Meth Psychiatr Res. 2001;10:126-133.
33. Hedges, LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Edu Behav Stat. 1981;6:107-128.
34. Cohen, J. Statistical analysis for the behavioral sciences, 2nd ed, Hillsdale: Lawrance Erlbaum Associates; 1988, 567pp.
35. Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863.
36. Hanagasi, HA, Gurvit, H, Unsalan, P, et al. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double‐blind, placebo‐controlled, multicenter study. Mov Disord. 2011;26:1851-1858.
37. Growdon, JH, Kieburtz, K, McDermott, MP, Panisset, M, Friedman, JH. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Neurology. 1998;50:1327-1331.
38. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol. 1989;46:1052-1060.
39. Kulisevsky, J, Garcia-Sanchez, C, Berthier, ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000;15:613-626.
40. Brusa, L, Bassi, A, Stefani, A, et al. Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Trans. 2003;110:373-380.
41. Brusa, L, Pavino, V, Massimetti, MC, Bove, R, Iani, C, Stanzione, P. The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson’s disease patients. Funct Neurol. 2013;28:13-17.
42. Fera, F, Nicoletti, G, Cerasa, A, et al. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson’s disease. Brain Res Bull. 2007;74:75-83.
43. Brusa, L, Tiraboschi, P, Koch, G, et al. Pergolide effect on cognitive functions in early-mild Parkinson’s disease. J Neural Trans. 2005;112:231-237.
44. Kwak, Y, Müller, ML, Bohnen, NL, Dayalu, P, Seidler, RD. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson’s disease. Behav Brain Res. 2012;230:116-124.
45. Costa, A, Peppe, A, Dell’Agnello, G, Caltagirone, C, Carlesimo, GA. Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia. 2009;47:1374-1381.
46. Relja, M, Klepac, N. A dopamine agonist, pramipexole, and cognitive functions in Parkinson’s disease. J Neurol Sci. 2006;248:251-254.
47. Antonelli, F, Ko, JH, Miyasaki, J, et al. Dopamine‐agonists and impulsivity in Parkinson’s disease: impulsive choices vs. impulsive actions. Human Brain Mapping. 2014;35:2499-2506.
48. Kieburtz, K, McDermott, M, Como, P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson’s disease. Neurology. 1994;44:1756 1756.
49. Dalrymple-Alford, JC, Jamieson, CF, Donaldson, IM. Effects of selegiline (deprenyl) on cognition in early Parkinson’s disease. Clin Neuropharmacol. 1995;18:348-359.
50. Dixit, SN, Behari, M, Ahuja, GK. Effect of selegiline on cognitive functions in Parkinson’s disease. J Assoc Physicians India. 1999;47:784-786.
51. Nasreddine, ZS, Phillips, NA, Bédirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatrics Soc. 2005;53:695-699.
52. Wechsler, D. Wechsler memory scale (WMS-III). San Antonio, TX: Psychological Corporation; 1997.
53. Milner, B. Interhemispheric differences in the localization of psychological processes in man. Br Med Bull. 1971;27:272-277.
54. Wechsler, D. A standardized memory scale for clinical use. J Psychol. 1945;19:87-95.
55. Wechsler, D. Measurement of adult intelligence. Baltimore, MD: Williams & Wilkins; 1958.
56. Wechsler, D. WAIS-R manual: Wechsler adult intelligence scale-revised. New York, NY: Psychological Corporation; 1981, 156pp.
57. Werheid, K, Hoppe, C, Thöne, A, Müller, U, Müngersdorf, M, Von Cramon, DY. The Adaptive Digit Ordering Test: clinical application, reliability, and validity of a verbal working memory test. Arch Clin Neuropsychol. 2002;17:547-565.
58. Canivez, GL. [Test review of the Weschler Adult Intelligence Scale-Fourth Edition]. In: Spies RA, Carlson JF, Geisinger KF, editors. The eighteenth mental measurements yearbook. Lincoln, NE: Buros Center for Testing; 2010.
59. Smith, A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services; 1973.
60. Iverson, GL, Lovell, MR, Collins, MW. Validity of ImPACT for measuring processing speed following sports-related concussion. J Clin Exp Neuropsychol. 2005;27(6):683-689.
61. Koh, CL, Lu, WS, Chen, HC, Hsueh, IP, Hsieh, JJ, Hsieh, CL. Test–retest reliability and practice effect of the oral-format Symbol Digit Modalities Test in patients with stroke. Arch Clin Neuropsychol. 2011;26(4):356-363.
62. Pereira, DR, Costa, P, Cerqueira, JJ. Repeated assessment and practice effects of the written Symbol Digit Modalities Test using a short inter-test interval. Arch Clin Neuropsychol. 2015;30(5):424-434.
63. Spinnler, H, Tognoni, G. Italien Groupe on the Neuropsychological Study of Ageing: Italian standardization and classification of neuropsychological tests. Ital J Neurol Sci. 1987;6:1-120.
64. Albert, M, Moss, M. The assessment of memory disorders in patients with Alzheimer’s disease. In: Squire L, Butters N, editors. Neuropsychology of memory. New York, NY: Guilford Press; 1984, pp. 236-246.
65. Uc, EY, McDermott, MP, Marder, KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009;73:1469-1477.
66. van Zomeren, AH, Brouwer, WH. Assessment of attention. In: Crawford JR, Parker, DM, McKinlay WW, editors. A handbook of neuropsychological assessment. Hove, UK: Lawrence Erlbaum; 1992, pp. 241-266.
67. Stroop, JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643-662.
68. Homack, S, Riccio, CA. A meta-analysis of the sensitivity and specificity of the Stroop Color and Word Test with children. Arch Clin Neuropsychol. 2004;19(6):725-743.
69. Army Individual Test Battery. Manual of directions and scoring. Washington, DC: War Department, Adjutant General’s Office; 1944.
70. Giovagnoli, AR, Del Pesce, M, Mascheroni, S, Simoncelli, M, Laiacona, M, Capitani, E. Trail making test: normative values from 287 normal adult controls. Italian J Neurol Sci. 1996;17(4):305-309.
71. Benton, AL, Hamsher, K, Sivan, AB. Multilingual aphasia examination, 3rd ed. Iowa City, IA: AJA Associates; 1983, 30pp.
72. Levin, BE, Llabre, MM, Reisman, S, et al. Visuospatial impairment in Parkinson’s disease. Neurology. 1991;41(3):365.
73. McCaffrey, RJ, Duff, K, Westervelt, HJ. editors Practitioner’s guide to evaluating change with neuropsychological assessment instruments. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000.
74. Riccio, CA, Hynd, GW. Validity of Benton’s judgement of Line Orientation Test. J Psychoeduc Assess. 1992;10(3):210-218.
75. Buschke, H, Fuld, PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24:1019 1019.
76. Benton, AL. Visual retention test, 4th ed. New York, NY: Psychological Corporation; 1974.
77. Delis, DC, Kramer, JH, Kaplan, E, Ober, BA., Fridlund, A. California Verbal Learning Test, Research Edition (CVLT) Manual. San Antonio, TX: The Psychological Corporation, Harcourt Brace Jovanovich, Inc; 1983.
78. Delis, DC, Kramer, JH, Kaplan, E, Thompkins, BAO. CVLT: California Verbal Learning Test-adult version: manual. San Antonio, TX: Psychological Corporation; 1987.
79. Lindskog, CO. [Test review of the California Verbal Learning Test, Second Edition, Adult Version]. In: Spies RA, Plake BS editors The sixteenth mental measurements yearbook. Lincoln, NE: Buros Center for Testing; 2005.
80. Rey, A. [The clinical psychological examination]. Paris: Presses Universitaires de France; 1964, French.
81. Delaney, RC, Prevey, ML, Cramer, J, Mattson, RH. Test-retest comparability and control subject data for the rey-auditory verbal learning test and rey-osterrieth/taylor complex figures. Arch Clin Neuropsychol. 1992;7(6):523-528.
82. Wilson, B, Cockburn, J, Baddeley, A. The Rivermead Behavioral Memory Test. Bury St. Edmunds, UK: Thames Valley Test; 1985.
83. Wilson, B, Cockburn, J, Baddeley, A, Hiorns, R. The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol. 1989;11(6):855-870.
84. Tupler, LA, Welsh, KA, Asare-Aboagye, Y, Dawson, DV. Reliability of the Rey-Osterrieth Complex Figure in use with memory-impaired patients. J Clin Exp Neuropsychol. 1995;17(4):566-579.
85. Wechsler, D. Weschler memory scale-revised manual. San Antonio, TX: The Psychological Corporation; 1987, 150pp.
86. Moore, PM, Baker, GA. Psychometric properties and factor structure of the Wechsler Memory Scale-Revised in a sample of persons with intractable epilepsy. J Clin Exp Neuropsychol. 1997;19(6):897-905.
87. Kaplan, EF, Goodglass, H, Weintraub, S. The Boston naming test, 2nd ed. Philadelphia: Lea & Febiger; 1983.
88. Harry, A, Crowe, SF. Is the Boston Naming Test still fit for purpose? Clin Neuropsychologist. 2014;28(3):486-504.
89. Freedman, M, Leach, L, Kaplan, E, Winocur, G, Shulman, KI, Delis, DC. Clock drawing: a neuropsychological analysis. Oxford, UK: Oxford University Press; 1994.
90. Matthews, CG, Klove, K. Instruction manual for the adult neuropsychology test battery. Madison, WI: University of Wisconsin Medical School; 1964.
91. Rey, A. [The psychological examination in cases of traumatic encepholopathy. Problems.]. Arch Psychol. 1941;28:215-285; French.
92. Osterrieth, PA. [The test of copying a complex figure]. Arch Psychol. 1944;30:206-356; French.
93. Hovestadt, A, De Jong, GJ, Meerwaldt, JD. Spatial disorientation in Parkinson’s disease: no effect of levodopa substitution therapy. Neurology. 1998;38:1802 1802.
94. Reitan, RM. Manual for administration of neuropsychological test batteries for adults and children. Indianapolis, IN: Indiana University medical Center; 1969.
95. Raven, JC, Court, JH, Raven, J, Kratzmeier, H. Advanced progressive matrices. London, UK: HK Lewis; 1988.
96. Raven, JC. Guide to the standard progressive matrices: sets A, B, C, D and E. London, UK: HK Lewis; 1960.
97. Flowers, KA, Robertson, C. The effect of Parkinson’s disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry. 1985;48:517-529.
98. Heaton, RK. Wisconsin card sorting test manual. Odessa: Psychological Assessment Ressources; 1981.
99. Nelson, HE. A modified card sorting test sensitive to frontal lobe defects. Cortex. 1976;12:313-324.
100. Bird, CM, Papadopoulou, K, Ricciardelli, P, Rossor, MN, Cipolotti, L. Monitoring cognitive changes: psychometric properties of six cognitive tests. Br J Clin Psychol. 2004;43(2):197-210.
101. Ferland, MB, Ramsay, J, Engeland, C, O’Hara, P. Comparison of the performance of normal individuals and survivors of traumatic brain injury on repeat administrations of the Wisconsin Card Sorting Test. J Clin Exp Neuropsychol. 1998;20(4):473-482.
102. Kirby, KN, Petry, NM, Bickel, WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol General. 1999;128:78.
103. Smith, CL, Hantula, DA. Methodological considerations in the study of delay discounting in intertemporal choice: a comparison of tasks and modes. Behav Res Methods. 2008;40(4):940-953.
104. Ballanger, B, van Eimeren, T, Moro, E, et al. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol. 2009;66:817-824.
105. Luria, AR. The frontal lobes and the regulation of behavior. In: Primbram, KH, Luria AR, editors. Psychophysiology of the frontal lobes. New York, NY: Academic Press; 1973, pp 3-26.
106. Christensen, AL. Luria’s neuropsychological investigation. Madrid: Pablo del Rio; 1974.
107. Penner, IK, Kobel, M, Stöcklin, M, Weber, P, Opwis, K, Calabrese, P. The Stroop task: comparison between the original paradigm and computerized versions in children and adults. Clin Neuropsychologist. 2012;26(7):1142-1153.
108. Krikorian, R, Bartok, J, Gay, N. Tower of London procedure: a standard method and developmental data. J Clin Exp Neuropsychol. 1994;16:840-850.
109. Michalec, J, Bezdicek, O, Nikolai, T, et al. A comparative study of tower of London scoring systems and normative data. Arch Clin Neuropsychol. 2017;32(3):328-338.
110. Lezak, MD. Neuropsychological assessment, 3rd ed. Oxford, UK: Oxford University Press; 1995, 1046pp.
111. Spreen, O, Strauss, E. A compendium of neuropsychological tests: administration, norms, and commentary. Oxford, UK: Oxford University Press; 1991, 442pp.
112. Benton, AL. Multi-lingual aphasia examination. Neuropsychologia. 1967;5:135-140.
113. Ruff, RM, Light, RH, Parker, SB, Levin, HS. Benton controlled oral word association test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329-338.
114. Lezak, MD, Howieson, DB, Bigler, ED, Tranel, D. Neuropsychological assessment, 5th ed. New York, NY: Oxford University Press; 2012.
115. Strauss, E, Sherman, EM, Spreen, O. A compendium of neuropsychological tests: administration, norms, and commentary. Oxford, NY: American Chemical Society; 2006.
116. Baddeley, AD, Hitch, G. Working memory. In: Bower GA, editor. Recent advances in learning and motivation, Vol. VIII, New York: Academic Press; 1974, pp. 47-89.
117. Baddeley, AD. The episodic buffer: a new component of working memory? Trends Cogn Sci. 2000;4:417-423.
118. Gotham, A, Brown, R, Marsden, C. Levodopa treatment may benefit or impair frontal function in Parkinson’s disease. Lancet. 1986;2:970-971.
119. Müller, T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener. 2012;1:10.
120. Poletti, M, Logi, C, Lucetti, C, et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33:691-694.
121. Riedel, O, Klotsche, J, Spottke, A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. J Neurol. 2008;255:255-264.
122. Hoops, S, Nazem, S, Siderowf, AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73:1738-1745.
123. Weintraub, D, Hauser, RA, Elm, JJ, Pagan, F, Davis, MD, Choudhry, A. Rasagiline for mild cognitive impairment in Parkinson’s disease: a placebo‐controlled trial. Mov Disord. 2016;31(5):709-714.
124. Frakey, LL, Friedman, JH. Cognitive effects of rasagiline in mild-to-moderate stage Parkinson’s disease without dementia. J Neuropsychiat Clin Neurosci. 2016;29(1):22-25.
125. Miyasaki, JM, Martin, W, Suchowersky, O, Weiner, WJ, Lang, AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58(1):11-17.
126. National Institute for Health and Care Excellence. Parkinson’s diease in over 20s: diagnosis and management. London: National Institute for Health and Care Excellence; 2006. Available at Accessed May 20, 2017.
127. U.S. Food and Drug Administration. U.S. Food and Drug Administration Home Page. Silver Spring, MD: U.S. Food and Drug Administration [updated May 24, 2017]. Available at Accessed May 26, 2017.
128. Molloy, SA, Rowan, EN, O’Brien, JT, McKeith, IG, Wesnes, K, Burn, DJ. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(12):1323-1328.
129. Bocanegra, Y, García, AM, Pineda, D, et al. Syntax, action verbs, action semantics, and object semantics in Parkinson’s disease: dissociability, progression, and executive influences. Cortex. 2015;69:237-254.


Type Description Title
Supplementary materials

Roy et al. supplementary material
Roy et al. supplementary material 1

 PDF (341 KB)
341 KB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed